Skip to content

Released Nov 13, 2026, after the close

10-Q filed Nov 13, 2026, 44 days after period end · 0001785530-26-000022

Q3 2026 · 10-Q
Revenue—
Net Income-$9.88MN/M vs Q3 2025N/M vs Q2 2026
EPS Diluted-$0.20N/M vs Q3 2025N/M vs Q2 2026
Operating Income-$10,054,000N/M
Operating Cash Flowderived-$8,967,000N/M

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ3 2026Q3 2025Q3 2024Q3 2023
Net Income-$9.88M-$16.37M-$16.67M-$8.29M
EPS Diluted-$0.20-$0.36-$0.38-$0.23

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Werewolf Therapeutics, Inc. · CIK 1785530 · Engraved from SEC EDGAR